MARQUEE collapses on tivantinib in NSCLC but other uses offer hope
This article was originally published in Scrip
Executive Summary
ArQule and Daiichi Sankyo have not completely lost hope for the c-Met inhibitor tivantinib (ARQ 197), but they have given up on treating patients who have non-small cell lung cancer (NSCLC) after the drug failed in the Phase III MARQUEE study to achieve statistical significance in the pivotal trial's primary endpoint of improvement in overall survival (OS).